Reproducibility of 99Tcm-MAG3 clearance calculated using the Bubeck method

Werner, Edgar; Körber, C.; Reiners, Chr.

doi:10.1097/00006231-199805000-00080

Cited by 4 publications

(11 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Our results were not very different from those of other authors, who estimated the reproducibility of 99m Tc-MAG3 single-or two-sample clearance with an SD of around 12% [14][15][16][17]. Kotzerke et al [14], Werner et al [15] and Russell and Dubovsky [16] performed the study retrospectively in different patient populations using a single-sample method, and calculated the reproducibility as 11.7, 11.7 and 12%, respectively.…”

Section: Discussioncontrasting

confidence: 54%

“…Inconsistent results of the reproducibility of 99m Tc-MAG3 clearance have been reported, ranging from 6.3 to 40.4% depending on the level of renal function, the clearance measurement technique applied and the time interval between the two studies [13][14][15][16][17][18][19]24]. However, in serial measurements of renal function, especially in patients with renal failure, good reproducibility of the test is vitally important for monitoring renal function and to ascertain whether changes in renal function are related to disease or to the limited reproducibility of the study.…”

Section: Discussionmentioning

confidence: 99%

“…Inconsistent results of the reproducibility of 99m Tc-MAG3 clearance have been reported, ranging from 6.3 to 40.4% depending on the level of renal function, the clearance measurement technique applied and the time interval between the two studies [13][14][15][16][17][18][19]24]. The assumption that the reproducibility is worse in patients with poor renal function is based mainly on these three patients, and has not been substantiated in a large group of patients [14,15]. However, most of the patients in these studies had normal renal function.…”

Section: Discussionmentioning

confidence: 99%

“…Kotzerke et al [14], Werner et al [15] and Russell and Dubovsky [16] performed the study retrospectively in different patient populations using a single-sample method, and calculated the reproducibility as 11.7, 11.7 and 12%, respectively. Kanazawa et al [17] carried out their study prospectively in healthy volunteers with the two-sample method at a 1 month interval, and the reproducibility was found to be 11.1%, which is in agreement with that of other studies [14][15][16] [24]. Moller and Widding [18] performed the gamma camera method for 99m Tc-MAG3 clearance estimation, and the reproducibility was found to be 12.4%, consistent with that of single-and twosample methods.…”

Section: Discussionmentioning

confidence: 99%

“…The utility of 99m Tc-MAG3 clearance has been extensively investigated in several studies [4][5][6], and it has been shown that the clearance of 99m Tc-MAG3 is closely correlated with the clearance of [ 131 I]OIH [6][7][8][9]. However, it has generally been reported that, although 99m Tc-MAG3 has very good accuracy [7][8][9][10][11][12], the results in terms of reproducibility are still controversial [13][14][15][16][17][18][19]. The reproducibility of the study is especially important in patients with renal failure in order to determine whether changes in renal function in serial measurements are related to progression, regression, resolution of the disease or poor reproducibility of the test.…”

Section: Introductionmentioning

confidence: 99%

See 4 more Smart Citations

Reproducibility of technetium-99m mercaptoacetyltriglycine clearance in patients with impaired renal function

Erdıl

Dede²,

Şen³

et al. 2006

Nuclear Medicine Communications

View full text Add to dashboard Cite

Single-sample methods give very poor reproducibility and accuracy and should not be used in patients with poor renal function. The reproducibility of 99mTc-MAG3 clearance using the multi-sample method (90 min) in patients with impaired renal function is 12.6%, which is similar to that in patients with good renal function and that obtained with other tubular agents. Whether this level of reproducibility is satisfactory for documenting serial changes in an individual patient with a 99mTc-MAG3 clearance below 100 ml/min/1.73 m2 depends on the expectation of the clinician.

show abstract

Section: Discussioncontrasting

confidence: 54%

Section: Discussionmentioning

confidence: 99%

“…Inconsistent results of the reproducibility of 99m Tc-MAG3 clearance have been reported, ranging from 6.3 to 40.4% depending on the level of renal function, the clearance measurement technique applied and the time interval between the two studies [13][14][15][16][17][18][19]24]. The assumption that the reproducibility is worse in patients with poor renal function is based mainly on these three patients, and has not been substantiated in a large group of patients [14,15]. However, most of the patients in these studies had normal renal function.…”

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

Reproducibility of technetium-99m mercaptoacetyltriglycine clearance in patients with impaired renal function

Erdıl

Dede²,

Şen³

et al. 2006

Nuclear Medicine Communications

View full text Add to dashboard Cite

show abstract

213Bi-DOTATOC receptor-targeted alpha-radionuclide therapy induces remission in neuroendocrine tumours refractory to beta radiation: a first-in-human experience

Kratochwil

Giesel

Bruchertseifer³

et al. 2014

Eur J Nucl Med Mol Imaging

341

254

View full text Add to dashboard Cite

PurposeRadiopeptide therapy using a somatostatin analogue labelled with a beta emitter such as 90Y/177Lu-DOTATOC is a new therapeutic option in neuroendocrine cancer. Alternative treatments for patients with refractory disease are rare. Here we report the first-in-human experience with 213Bi-DOTATOC targeted alpha therapy (TAT) in patients pretreated with beta emitters.MethodsSeven patients with progressive advanced neuroendocrine liver metastases refractory to treatment with 90Y/177Lu-DOTATOC were treated with an intraarterial infusion of 213Bi-DOTATOC, and one patient with bone marrow carcinosis was treated with a systemic infusion of 213Bi-DOTATOC. Haematological, kidney and endocrine toxicities were assessed according to CTCAE criteria. Radiological response was assessed with contrast-enhanced MRI and 68Ga-DOTATOC-PET/CT. More than 2 years of follow-up were available in seven patients.ResultsThe biodistribution of 213Bi-DOTATOC was evaluable with 440 keV gamma emission scans, and demonstrated specific tumour binding. Enduring responses were observed in all treated patients. Chronic kidney toxicity was moderate. Acute haematotoxicity was even less pronounced than with the preceding beta therapies.ConclusionTAT can induce remission of tumours refractory to beta radiation with favourable acute and mid-term toxicity at therapeutic effective doses.Electronic supplementary materialThe online version of this article (doi:10.1007/s00259-014-2857-9) contains supplementary material, which is available to authorized users.

show abstract

[18F]-PSMA-1007-PET for evaluation of kidney function

Rassek,

Schäfers,

Rahbar

et al. 2023

Nuklearmedizin

View full text Add to dashboard Cite

Purpose Prostate-specific membrane antigen (PSMA) is present in the proximal tubule cells of the kidneys. This results in high renal tracer uptake in PSMA-PET, which may contain useful information on renal function. As part of the evaluation for [177Lu]-PSMA therapies, patients undergo PSMA-PET and additional [99mTc]-mercapto-acetyltriglycine (MAG3) scintigraphy to assess renal function. Aim of this study was to evaluate estimation of renal function with [18F]-PSMA-1007-PET/CT (PSMA-PET) by comparison to timely MAG3-scintigraphies. Materials and Methods We retrospectively investigated 73 prostate cancer patients with 93 timely available PSMA-PET/CT, MAG3-scintigraphies and serum creatinine. For determination of split renal function in PSMA-PET/CT, we evaluated the relative unilateral total renal PSMA uptake, i.e. SUVmean multiplied by the renal volume (SRFPSMA-TOTAL) and relative unilateral maximal standardized uptake value (SRFSUV). These were compared to MAG3 split renal function (SRFMAG3) using Pearson correlation and receiver operating characteristics analysis. For determination of global renal function, correlation of bilateral total renal PSMA uptake with MAG3 tubular excretion rate and serum creatinine was assessed. Results SRFMAG3 was strongly correlated with SRFPSMA-TOTAL (r= 0.872, p<0.001) and with SRFSUV (r=0.815, p<0.001). Relevant abnormalities of SRFMAG3 (unilateral renal function < 25 %) could be detected with sensitivities and specificities of 90% and 92% for SRFPSMA-TOTAL, and 80% and 95% for SRFSUV. Measures of absolute renal function were only weakly correlated with bilateral total renal PSMA uptake. Conclusion Renal [18F]-PSMA-1007 uptake allowed to quantify renal split function with good accuracy based on SRFPSMA-TOTAL or SRFSUV.

show abstract

Reproducibility of 99Tcm-MAG3 clearance calculated using the Bubeck method

Cited by 4 publications

References 0 publications

Reproducibility of technetium-99m mercaptoacetyltriglycine clearance in patients with impaired renal function

Reproducibility of technetium-99m mercaptoacetyltriglycine clearance in patients with impaired renal function

213Bi-DOTATOC receptor-targeted alpha-radionuclide therapy induces remission in neuroendocrine tumours refractory to beta radiation: a first-in-human experience

[18F]-PSMA-1007-PET for evaluation of kidney function

Contact Info

Product

Resources

About